Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases

Inclusion criteria

• Age ≥ 18 years.
• Patient with hyperthyroidism (Graves' disease, toxic nodular goiter (TNG) or toxic multi hetero nodular goiter (GMHNT)) relevant to an indication for 131I treatment.
• Patient with no risk of iodine saturation.
• Patient able to maintain a sitting position in an armchair for 10 minutes with chin raised and held by a "chin rest" with head in extension.
• WHO index ≤ 1.
• For non-menopausal patients, use of an effective contraceptive method at the start of the clinical investigation and throughout the clinical investigation, and a negative pregnancy test before administration of the tracer activity and the 131I therapeutic activity.
• Patient signed informed consent prior to inclusion in the clinical investigation and prior to any specific procedure for the clinical investigation.
• Patient affiliated to a social security scheme in France.

Exclusion criteria

• Absence of clinical or biological hyperthyroidism.
• Patient with a contraindication to 131I treatment.
• Existence of one or more nodule(s) associated with hyperthyroidism at risk of malignancy according to EU-TIRADS and Bethesda criteria if cytopuncture performed.
• Active orbithopathy associated with Graves' disease.
• Contrast-enhanced examination performed within the two months prior to inclusion.
• Use of iodised products for skin disinfection (Betadine) in the 4 weeks prior to inclusion.
• Treatment with Amiodarone and derivatives in the 18 months prior to inclusion. (Ioduria test to rule out iodine saturation).
• Pregnant or breast-feeding woman.
• Patient planning pregnancy within 6 months of 131I treatment.
• Any psychological, family, geographical or sociological condition that makes it impossible to comply with the medical monitoring and/or procedures set out in the clinical investigation protocol.
• Any co-existing medical condition which, in the opinion of the investigator, could constitute a risk by participating in this study.
• Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).